Dengue Testing Market
Dengue Testing Market Study by ELISA-Based Tests, RT-PCR-Based Tests, and Dengue IgG/IgM Rapid Tests Done at Hospitals, Public Health Laboratories, Diagnostic Centers, and Others from 2024 to 2034
Analysis of Dengue Testing Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Dengue Testing Market Outlook
The projected worth of the global dengue testing market is US$ 681.9 million in 2024. With a CAGR of 6.1% throughout the projected period and is anticipated to attain US$ 1,232.8 million by 2034.
Due to an increase in dengue illnesses worldwide, the dengue testing industry is anticipated to expand. Market expansion for dengue testing is aided by rising public awareness, government programs to combat disease, and developments in diagnostic technology.
The motivating factors are the need for prompt and accurate diagnosis as well as emerging economies with high incidence rates. Obstacles, including the inadequate healthcare infrastructure in certain regions, can hinder the dengue testing kit market from expanding. The dengue virus testing market ought to expand due to the demand for efficient dengue testing methods.
Dynamics Thrusting the Dengue Testing Industry Forward
The increasing incidence of dengue disease globally compels the dengue testing market. Accurate and prompt diagnostic testing is becoming necessary as the number of reported cases rises.
The market growth for dengue testing is fueled by ongoing improvements in diagnostic technologies, including point-of-care testing, serological testing, and nucleic acid testing (NAT). The effectiveness of dengue diagnostics is increased by these technologies, which also provide faster results, increased sensitivity, and increased specificity.
The dengue diagnostics industry is primarily driven by government measures to stop the spread of dengue and by healthcare policies emphasizing early diagnosis and treatment. Access to testing services is made more widely possible by financial assistance, subsidies, and regulatory structures.
Aedes mosquito distribution and prevalence are directly impacted by the effects of climate change, which include modifications to temperature and precipitation patterns. This, in turn, affects dengue incidence, escalating the demand for dengue testing in areas that traditionally can't have been impacted.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 681.9 million |
| Forecasted Market Value (2034F) | US$ 1,232.8 million |
| Global Market Growth Rate (2024 to 2034) | 6.1% |
| Dengue IgG/IgM Rapid Tests Segment Growth Rate (2024 to 2034) | 6.4% |
| Others End-user Segment Growth Rate (2024 to 2034) | 6.8% |
| North America Market Share (2024) | 4.8% |
| Latin America Market Share (2024) | 6.4% |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Impediments to Growth in the Dengue Diagnostic Sector
The growth of the dengue testing market can be constrained by the general public's lack of understanding about the significance of early dengue identification and testing. It is essential to inform individuals about the advantages of testing in areas where dengue is a common disease. Dengue testing is not widely used in poorer nations due to inadequate healthcare infrastructure and restricted access to medical facilities.
The market growth for dengue testing can be slowed by healthcare organizations' or professionals' resistance to implementing novel testing procedures or departing from conventional diagnostic techniques. Tight legal restrictions and lengthy approval procedures for novel testing techniques impede the release of cutting-edge products, hampering the growth of the dengue diagnostic market.
Country-wise Analysis
North America is anticipated to develop at a CAGR of 4.8% through 2034. Rising product demand in leading countries, especially the United States and Canada, is the primary catalyst behind the spike. The United States tops by 2034 with an estimated 65.6% of the dengue testing kit market share.
Latin America is anticipated to advance at a 6.4% CAGR through 2034. Brazil has emerged as the dominant force, with a 40.9% share of the dengue testing market by 2034.
What Growth Opportunities Exist in the North America Dengue Virus Testing Market?
“Point-of-Care Testing Emerges as a Notable Trend in North America's Dengue Diagnostics”
The dengue diagnostic market in the United States is distinguished by a need for adaptable diagnostic solutions due to its diversified population and large influx of foreign visitors. In the United States, there is an increasing focus on proactive dengue testing methods due to public health campaigns and initiatives.
In line with the country's emphasis on effective healthcare solutions, the United States market shifts towards quick and precise diagnostic techniques. The United States will top the industry in 2024 with an estimated 65.2% of the dengue testing market.
| Attributes | Details |
|---|---|
| United States Market CAGR | 4.9% |
| United States Market Size (2024) | US$ 71 million |
| Canada Market CAGR | 5.8% |
| Canada Market Size (2024) | US$ 7 million |
The demand for dengue testing in Canada is impacted by worldwide trends since vector-borne illnesses are becoming more widespread due to increased travel and climatic changes. The Canada dengue virus testing market is defined by an increasing consciousness of dengue hazards, which has led healthcare systems to incorporate thorough testing procedures.
The cooperative character of the Canadian healthcare system encourages research and development partnerships and shapes the dynamic environment for dengue testing solutions. Canada to reach a valuation of US$ 12 million by 2034.
What Growth Opportunities Exist in the Latin America Dengue Testing Market?
“Increasing Awareness Accelerate Adoption of Dengue Testing in Latin America.”
Brazil has a significant demand for dengue testing because of its tropical climate, which makes it an ideal place for mosquito breeding. The sales of dengue testing are experiencing growth due to the Brazilian government's strong public health policies, which prioritize early identification and prevention.
Brazil's socioeconomic heterogeneity affects the need for various dengue diagnostic techniques that can be used in urban and rural healthcare environments. Brazil tops the industry in 2024 with an estimated 39.6% of the dengue virus testing market.
| Attributes | Details |
|---|---|
| Brazil Market CAGR | 6.8% |
| Brazil Market Size (2024) | US$ 47 million |
| Chile Market CAGR | 6.0% |
| Chile Market Size (2024) | US$ 30 million |
The market for timely and precise dengue testing solutions is expanding as a result of the Chile government's emphasis on preventive healthcare measures. The demand for quick and accurate diagnostics is enhanced by the country's strict dengue testing requirements, which are required due to its crucial location and international connectivity.
The demand for cutting-edge dengue testing methods is fueled by Chile's well-established healthcare infrastructure, which promotes awareness and preparedness for dengue outbreaks. Chile can reach a valuation of US$ 53 million by 2034.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Outlook
With 46.2% of the market share by 2034, the ELISA-based tests category is expected to lead the market, demonstrating its significant influence on the state of the sector. Likewise, the dengue IgG/IgM rapid test category can attain a 34.5% market share by 2034, underscoring its noteworthy contribution to market stability and variety.
When considering end-user trends, it is projected that hospitals can possess an imposing market share of 45.7% by 2034 and exert a significant impact. This highlights the importance of healthcare institutions in the developing healthcare market by highlighting their crucial role in accepting and adopting diagnostic testing for dengue.
What Makes ELISA-Based Tests the Preferred Choice for Dengue Virus Detection?
“Established Reliability Makes ELISA-Based Tests a Preferred Choice for Accurate Diagnostic Results.”
| ELISA Based Tests | Details |
|---|---|
| Market Size (2024) | US$ 320.3 million |
| Market CAGR (2024 to 2034) | 5.9% |
| Dengue IgG/IgM Rapid Tests | Details |
|---|---|
| Market Size (2024) | US$ 229.1 million |
| Market CAGR (2024 to 2034) | 6.4% |
Due to their proven accuracy and dependability in identifying dengue antibodies, ELISA-based tests account for most dengue testing sales. The excellent sensitivity and specificity of the ELISA-based test segment in identifying dengue virus components has led to its widespread adoption. The ELISA-based test segment partly leads in dengue testing sales because of its established clinical track record.
In 2024, the ELISA-based test segment is likely to account for 47.0% of the product type category. However, the dengue IgG/IgM rapid tests sector is scheduled to have a 33.6% share within the product type category.
What Factors Contribute to Hospitals Being the Primary Choice for Dengue Testing?
“Public Trust in Hospital Testing Facilities Contributes to The Segment's Sales Leadership.”
| Hospital | Details |
|---|---|
| Market Size (2024) | US$ 310.3 million |
| Market Share (2024) | 45.5% |
| Diagnostic Centers | Details |
|---|---|
| Market Size (2024) | US$ 207.2 million |
| Market Share (2024) | 30.4% |
Hospitals lead the dengue testing sales partly because of patient trust and confidence in hospital environments. Hospitals' demand for dengue testing services, essential to responding to epidemics, is increasing.
Hospitals are essential centers for diagnosing and treating infectious diseases like dengue because they offer a wide range of medical services. As main healthcare facilities, hospitals see more patients for dengue testing.
A CAGR of 6.2% is estimated for the hospital segment under the product type category between 2024 and 2034. Following the hospital segment, the diagnostic center segment is anticipated to progress at a CAGR of 6.1% through 2034.
Competitive Analysis
The dengue testing market is characterized by fierce competition brought on by an increase in dengue illnesses worldwide. The prominent dengue testing vendors are concentrating on partnerships, strategic collaborations, and global expansions to increase their market presence. An increase influences the competitive dynamics in research and development efforts for creative testing solutions.
Manufacturers of dengue testing emphasize efficiency and cost-effectiveness to profit from the rising demand for quick and accurate diagnostic instruments. A combination of reputable dengue testing manufacturers and promising dengue testing providers compete for market share using a range of different tactics.
Notable Advancements
- A combined RT-PCR test kit for detecting Sars-CoV-2 and monsoon infections was made available by Mylab Discovery Solutions in May 2022. In addition to germs that cause malaria, chikungunya, dengue, Zika, leptospirosis, and salmonellosis, the test kit can identify parasites that cause leishmaniasis.
- Anitoa System unveiled a mobile RT-PCR molecular test to detect dengue virus infections in May 2022.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Segmentation of Dengue Testing Market Research
-
By Product Type:
- ELISA Based Tests
- RT-PCR Based Tests
- Dengue IgG/IgM Rapid Tests
-
By End User:
- Hospitals
- Public Health Laboratory
- Diagnostic Centers
- Others
-
By Region:
- North America
- Latin America
- East Asia
- South Asia and Pacific
- Western Europe
- Eastern Europe
- The Middle East and Africa
- FAQs -
What Was the Value of The Dengue Testing Market in 2019?
The global dengue testing market was worth US$ 507.1 million in 2019.
What Is the Sales Outlook for Dengue Testing Market in 2024?
The sales of dengue testing are likely to be valued at US$ 681.9 million in 2024.
What Is the Demand Forecast for Dengue Testing Market?
Demand for dengue testing is projected to reach a market value of US$ 1,232.8 million by the end of 2034.
What Is the Adoption Growth Projection for the Dengue Testing Market?
Adoption of dengue testing is projected to rise at a CAGR of 6.1% through 2034.
At What CAGR Is the Dengue Testing Market in North America Predicted to Grow?
The North America dengue testing market is forecast to expand at a CAGR of 4.8% through 2034.
At What Rate Is the Dengue Testing Market in Latin America Predicted to Grow?
The Latin America dengue virus testing market is forecast to expand at a CAGR of 6.4% through 2034.
Dengue Testing Market